Evercore ISI Adjusts Baxter International Price Target to $22 From $23, Maintains Outperform Rating

robot
Abstract generation in progress

Evercore ISI has adjusted its price target for Baxter International (NYSE: BAX) to $22, down from $23, while reaffirming its Outperform rating. The announcement was made on April 6, 2026, at 09:45 am EDT. This change reflects the analyst firm’s updated valuation perspective on the medical technology company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin